keyword
MENU ▼
Read by QxMD icon Read
search

aliskiren

keyword
https://www.readbyqxmd.com/read/28767167/the-impact-of-age-and-sex-on-the-reporting-of-cough-and-angioedema-with-ras-inhibitors-a-case-non-case-study-in-vigibase
#1
Fawaz F Alharbi, Anzhelika A V Kholod, Patrick C Souverein, Ronald H Meyboom, Mark C H de Groot, Anthonius de Boer, Olaf H Klungel
The purpose of this study was to assess the impact of age and sex on the reporting of cough and angioedema related to renin angiotensin system (RAS) inhibitors. A case/non-case study was performed in VigiBase. Two case groups were identified, reports of cough and reports of angioedema and non-cases were all reports of all other adverse events. Logistic regression analysis was used to assess the association between reporting of cough and angioedema with each class of RAS inhibitors stratified by age/sex and to control for confounding...
August 2, 2017: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/28765966/aliskiren-has-chondroprotective-efficacy-in-a-rat-model-of-osteoarthritis-through-suppression-of-the-local-renin-angiotensin-system
#2
Kaizhong Yan, Yixin Shen
The local renin-angiotensin system (RAS) has been reported to have an important role in the pathogenesis and progression of metabolic bone diseases, including osteoarthritis (OA). Aliskiren is the first in a new class of orally effective direct renin inhibitors and is approved for the treatment of hypertension in humans. However, its efficacy in patients with OA is unknown. A rat model of OA was induced to investigate the potential efficacy of aliskiren. Effects of aliskiren on the cartilage structure were detected by safranin O staining and its effects on the widths of the proliferation zone and hypertrophic zone (HZ) of chondrocytes were analyzed by Masson's staining...
July 28, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28753620/treatment-combining-aliskiren-with-paricalcitol-is-effective-against-progressive-renal-tubulointerstitial-fibrosis-via-dual-blockade-of-intrarenal-renin
#3
Sungjin Chung, Soojeong Kim, Minyoung Kim, Eun Sil Koh, Seok Joon Shin, Cheol Whee Park, Yoon Sik Chang, Ho-Shik Kim
The aim of this study was to assess any potential additive effects of a treatment combining aliskiren with paricalcitol on reducing renal fibrosis. C57BL/6J mice were treated individually with aliskiren and/or paricalcitol until 7 days after initiation of unilateral ureteral obstruction (UUO).In obstructed kidneys of UUO mice, monotherapy with aliskiren or paricalcitol significantly attenuated interstitial fibrosis, collagen IV accumulation, and α-smooth muscle actin- and terminal deoxynucleotidyl transferase-mediated biotin nick end-labeling-positive cells...
2017: PloS One
https://www.readbyqxmd.com/read/28751628/aliskiren-therapy-in-hypertension-and-cardiovascular-disease-a-systematic-review-and-a-meta-analysis
#4
REVIEW
Shufang Fu, Xin Wen, Fei Han, Yin Long, Gaosi Xu
The efficacy and safety of aliskiren combination therapy with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in patients with hypertension and cardiovascular disease remains attractive attention. We searched the Cochrane Central Register, the Clinical Trials Registry, EMBASE, MEDLINE and PubMed for relevant literatures up to January 2017. A total of 13 randomized controlled trials (RCTs) with 12222 patients were included in this study, and the combined results indicated that aliskiren in combination therapy with ACEIs or ARBs had remarkable effects in reducing systolic blood pressure (SBP) [weighted mean differences (WMD), -4...
July 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28724547/long-term-effects-of-a-renin-inhibitor-versus-a-thiazide-diuretic-on-arterial-stiffness-and-left-ventricular-diastolic-function-in-elderly-hypertensive-patients
#5
Yoshiyuki Okada, Shigeki Shibata, Naoki Fujimoto, Stuart Alexander Best, Benjamin D Levine, Qi Fu
Arterial stiffness and cardiac function are important predictors of cardiovascular events in patients with hypertension even with adequate blood pressure (BP) control. We evaluated whether a direct renin inhibitor, aliskiren, reduces arterial stiffness and modulates left ventricular function compared with a diuretic, hydrochlorothiazide, in elderly hypertensives. Twenty one hypertensives [67±14 (SD) yrs] were randomly assigned to receive 6-month aliskiren (n=11) or hydrochlorothiazide (n=10) based therapy...
July 19, 2017: American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
https://www.readbyqxmd.com/read/28700686/renin-inhibition-improves-metabolic-syndrome-and-reduces-angiotensin-ii-levels-and-oxidative-stress-in-visceral-fat-tissues-in-fructose-fed-rats
#6
Chu-Lin Chou, Heng Lin, Jin-Shuen Chen, Te-Chao Fang
Renin-angiotensin system in visceral fat plays a crucial role in the pathogenesis of metabolic syndrome in fructose-fed rats. However, the effects of renin inhibition on visceral adiposity in metabolic syndrome are not fully investigated. We investigated the effects of renin inhibition on visceral adiposity in fructose-fed rats. Male Wistar-Kyoto rats were divided into 4 groups for 8-week experiments: Group Con (standard chow diet), Group Fru (high-fructose diet; 60% fructose), Group FruA (high-fructose diet and concurrent aliskiren treatment; 100 mg/kg body weight [BW] per day), and Group FruB (high-fructose diet and subsequent, i...
2017: PloS One
https://www.readbyqxmd.com/read/28690496/dynamic-changes-in-the-renin-angiotensin-aldosterone-system-and-the-beneficial-effects-of-renin-angiotensin-aldosterone-inhibitors-on-spatial-learning-and-memory-in-a-rat-model-of-chronic-cerebral-ischemia
#7
Xinwu Huang, Guozhou Lu, Guochun Li, Hua Li, Beihua Li, Jiazhen Yin, Shousong Cao
Renin-angiotensin-aldosterone system (RAAS) plays an important role in the regulation of blood pressure and brain function. Therefore, we studied the dynamic changes in the RAAS in the blood, cerebral cortex, and hippocampus and the effects of RAAS inhibitors on spatial learning and memory and hippocampal apoptosis in a rat model of chronic cerebral ischemia (CCI) established by bilateral ligation of the common carotid arteries of rats. The levels of renin, angiotensin II (Ang II), and aldosterone (ALD) in the plasma, and the homogenates of the left side of cerebral cortex and whole hippocampus of rats were detected on day 1, 3, 7, 14, 21, and 30 by radioimmunoassay...
2017: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/28666704/systemic-and-tissue-specific-effects-of-aliskiren-on-the-raas-and-carbohydrate-lipid-metabolism-in-obese-patients-with-hypertension
#8
Stefan Engeli, Marcus May, Juerg Nussberger, A H Jan Danser, William P Dole, Margaret F Prescott, Marion Dahlke, Sylvie Stitah, Parasar Pal, Michael Boschmann, Jens Jordan
Aliskiren penetrates adipose and skeletal muscle in hypertensive patients with abdominal obesity and reduces renin-angiotensin-aldosterone system activity. After discontinuation, blood pressure-lowering effects are observed possibly through drug-tissue binding. We performed microdialysis evaluation of adipose tissue and skeletal muscle before and during an insulin-modified frequently sampled intravenous glucose tolerance test (IM-FSIGT). Aliskiren 300 mg (n = 8) or amlodipine 5 mg (n = 8) once daily were administered during a 12-week randomized treatment period...
June 12, 2017: Journal of the American Society of Hypertension: JASH
https://www.readbyqxmd.com/read/28598381/renin-inhibition-with-aliskiren-a-decade-of-clinical-experience
#9
REVIEW
Nikolaos-Dimitrios Pantzaris, Evangelos Karanikolas, Konstantinos Tsiotsios, Dimitrios Velissaris
The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathophysiology of arterial hypertension as well as in more complex mechanisms of cardiovascular and renal diseases. RAAS-blocking agents like angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers, have long been key components in the treatment of essential hypertension, heart failure, diabetic nephropathy, and chronic kidney disease, showing benefits well beyond blood pressure reduction. Renin blockade as the first step of the RAAS cascade finally became possible in 2007 with the approval of aliskiren, the first orally active direct renin inhibitor available for clinical use and the newest antihypertensive agent on the market...
June 9, 2017: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/28537000/advances-in-clinical-cardiology-2016-a-summary-of-the-key-clinical-trials
#10
REVIEW
Alastair Gray, Conor McQuillan, Ian B A Menown
INTRODUCTION: The findings of many new cardiology clinical trials over the last year have been published or presented at major international meetings. This paper aims to describe and place in context a summary of the key clinical trials in cardiology presented between January and December 2016. METHODS: The authors reviewed clinical trials presented at major cardiology conferences during 2016 including the American College of Cardiology (ACC), European Association for Percutaneous Cardiovascular Interventions (EuroPCR), European Society of Cardiology (ESC), European Association for the Study of Diabetes (EASD), Transcatheter Cardiovascular Therapeutics (TCT), and the American Heart Association (AHA)...
July 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28509129/successful-long-term-effects-of-direct-renin-inhibitor-aliskiren-in-a-patient-with-atherosclerotic-renovascular-hypertension
#11
Norihiko Morisawa, Naoki Sugano, Takafumi Yamakawa, Satoru Kuriyama, Takashi Yokoo
A 64-year-old man visited our hospital with complaints of misty vision and ophthalmalgia. On admission, his blood pressure (BP) was high at 220/135 mmHg with no past history of hypertension, and he had choked discs. He was tentatively diagnosed as having idiopathic intracranial hypertension, and was later found to have atherosclerotic unilateral renovascular hypertension (RVH) based upon the extremely high plasma renin activity together with the radiological image tests. On day 3, combined antihypertensive therapies consisting of oral angiotensin II receptor blocker (ARB) and Ca channel blocker (CCB) along with intravenous CCB induced an abrupt BP lowering which led to deterioration of his renal function, progressing into acute kidney injury (AKI)...
May 2017: CEN Case Reports
https://www.readbyqxmd.com/read/28498232/antihypertensive-drugs-aliskiren-nebivolol-and-olmesartan-reduce-hypertension-by-reducing-endothelial-microparticle-and-regulating-angiogenesis
#12
Moon Jain, Vivek Bhosale, Dipti Tripathi, Himalaya Singh, Niharika Pal, Kashif Hanif, Kumaravelu Jagavelu
The accelerated generation of endothelial microparticles (EMP) and impaired angiogenesis are the markers of vascular pathology during various cardiovascular and inflammatory conditions including hypertension. Since, studies comparing the effects of antihypertensive agents on these two parameters are limited; the present study was designed to compare the effects of three antihypertensive agents: aliskiren, nebivolol, and olmesartan, on the EMP generation and angiogenesis. Changes in the hemodynamic parameters and serum EMP count were determined post 3 weeks of the drug treatments [aliskiren (30 mg/kg), nebivolol (10 mg/kg), or olmesartan (5 mg/kg) per orally] in L-NAME induced rat model of hypertension...
May 9, 2017: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/28464775/renoprotection-by-direct-renin-inhibition-a-systematic-review-and-meta-analysis
#13
Nikolaos Louvis, James Coulson
Even mild abnormalities of the renal structure or function can increase the risk of mortality and complications in other organs. Therefore, safe and effective treatments are necessary in order to influence the progression of renal disease. We used 2 methods to assess the renoprotective effects of aliskiren: 1) a statistical analysis of clinical trials that investigated aliskiren-induced renoprotection, in terms of changes in serum creatinine concentration (sCr) or estimated glomerular filtration rate (eGFR), and, 2) clinical trials that investigated the renoprotective effects of aliskiren with respect to changes in albuminuria or proteinuria...
May 1, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28455996/aliskiren-reduces-albuminuria-after-kidney-transplantation
#14
Leszek Tylicki, Alicja M Debska-Slizien, Slawomir Lizakowski, Milena Przybylska, Zbigniew Heleniak, Marcin Renke, Andrzej L Chamienia, Bogdan Biedunkiewicz, Przemyslaw Rutkowski, Sylwia Małgorzewicz, Boleslaw Rutkowski
BACKGROUND: The renoprotective effects of the direct renin inhibitor, aliskiren, in renal transplant recipients have been supposed, but not finally proven. We performed an exploratory double-blind, losartan controlled, cross-over study to evaluate the influence of aliskiren, direct renin inhibitor, on albuminuria and other surrogate markers of kidney injury in patients after renal transplantation. The safety of this therapy was also evaluated. METHOD: 16 of 18 patients (12 M, 4 F), 48...
2017: Acta Biochimica Polonica
https://www.readbyqxmd.com/read/28449154/dual-raas-blockade-with-aliskiren-in-patients-with-severely-impaired-chronic-kidney-disease
#15
Franz Maximilian Rasche, Claudia Joel, Thomas Ebert, Thomas Frese, Filip Barinka, Volker Busch, Wilma Gertrud Rasche, Tom H Lindner, Jochen Schneider, Stephan Schiekofer
Dual renin-angiotensin-aldosterone blockade (dRAASb) is purposed in the prevention of the cardiorenal syndrome (CRS). However, all attempts with dRAASb even in patients with moderate impaired chronic kidney disease (CKD) were terminated due to the typical severe adverse events (SAE), e. g., hyperkalemia and rise of serum creatinine. The aim of our study with the direct renin inhibitor aliskiren was to evaluate the effect of dRAASb with a washout phase in patients with severely advanced CKD. We have studied 45 patients (G3b to 4, A2 and >A3; median glomerular filtration rate (GFR) CKD-EPI 31 (23-40) ml/min per 1...
April 27, 2017: Experimental and Clinical Endocrinology & Diabetes
https://www.readbyqxmd.com/read/28409014/comparable-effect-of-aliskiren-or-a-diuretic-added-on-an-angiotensin-ii-receptor-blocker-on-augmentation-index-in-hypertension-a-multicentre-prospective-randomised-study
#16
Toru Miyoshi, Takashi Murakami, Satoru Sakuragi, Masayuki Doi, Seiji Nanba, Atsushi Mima, Youkou Tominaga, Takafumi Oka, Yutaka Kajikawa, Kazufumi Nakamura, Hiroshi Ito
BACKGROUND: The effects of antihypertensive drug combination therapy on central blood pressure (BP) and augmentation index (AI) have not been fully elucidated. We investigated the effects of the direct renin inhibitor, aliskiren, or a diuretic added to an angiotensin II receptor blocker on AI in patients with essential hypertension. METHODS: A 24-week, prospective, multicentre, randomised, open-label study enrolled 103 patients already treated with valsartan. Participants were randomly allocated to receive either valsartan with aliskiren (V+A), or valsartan with trichlormethiazide (V+T)...
2017: Open Heart
https://www.readbyqxmd.com/read/28379619/blood-pressure-lowering-efficacy-of-renin-inhibitors-for-primary-hypertension
#17
REVIEW
Vijaya M Musini, Kendra Ak Lawrence, Patricia M Fortin, Ken Bassett, James M Wright
BACKGROUND: Hypertension is a chronic condition associated with an increased risk of mortality and morbidity. Renin is the enzyme responsible for converting angiotensinogen to angiotensin I, which is then converted to angiotensin II. Renin inhibitors are a new class of drugs that decrease blood pressure (BP) by preventing the formation of both angiotensin I and angiotensin II. OBJECTIVES: To quantify the dose-related BP lowering efficacy of renin inhibitors compared to placebo in the treatment of primary hypertension...
April 5, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28356668/targeting-renin-angiotensin-system-in-malignant-hypertension-in-atypical-hemolytic-uremic-syndrome
#18
V Raghunathan, S K Sethi, M A Dragon-Durey, M Dhaliwal, R Raina, P Jha, S B Bansal, V Kher
Hypertension is common in hemolytic uremic syndrome (HUS) and often difficult to control. Local renin-angiotensin activation is believed to be an important part of thrombotic microangiopathy, leading to a vicious cycle of progressive renal injury and intractable hypertension. This has been demonstrated in vitro via enhanced tissue factor expression on glomerular endothelial cells which is enhanced by angiotensin II. We report two pediatric cases of atypical HUS with severe refractory malignant hypertension, in which we targeted the renin-angiotensin system by using intravenous (IV) enalaprilat, oral aliskiren, and oral enalapril with quick and dramatic response of blood pressure...
March 2017: Indian Journal of Nephrology
https://www.readbyqxmd.com/read/28228402/aliskiren-increases-aquaporin-2-expression-and-attenuates-lithium-induced-nephrogenic-diabetes-insipidus
#19
Yu Lin, Tiezheng Zhang, Pinning Feng, Miaojuan Qiu, Qiaojuan Liu, Suchun Li, Peili Zheng, Yonglun Kong, Moshe Levi, Chunling Li, Weidong Wang
The direct renin inhibitor aliskiren has been shown to retain and persist in medullary collecting ducts even after treatment was discontinued, suggesting a new mechanism of action for this drug. The purpose of the present study was to investigate whether aliskiren regulates renal aquaporin expression in the collecting ducts and improves urinary concentrating defect induced by lithium in mice. The mice were either fed with normal chow or LiCl diet (40mM/kg dry food/day for 4 days and 20mM/kg dry food/day for last 3 days) for seven days...
February 22, 2017: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/28199630/end-of-the-road-for-aliskiren-in-heart-failure
#20
Andros Tofield
No abstract text is available yet for this article.
February 1, 2017: European Heart Journal
keyword
keyword
80744
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"